ImmunityBio, Inc. announced two key executive appointments that bring industry-leading market growth and access experience to the company. Helen Luu will serve asthe company’s first Chief Commercial Officer, joiningImmunityBio from her position as CEO of CAR-T developer Cell BT. The company also named Sigrid Schreiner as Senior Vice President of Global Market Access. She joins the company from Stemline Therapeutics (now Menarini Group), a global commercial-stage oncology therapeutics company. As Chief CommercialOfficer, Luu will take on the vital responsibilities of the company’s global commercial strategy, including the design and execution of expansion into the oncology and urology markets, as well as establishing key external alliances to support the commercial success of ImmunityBio. With more than 16 years of experience in multichannel and specialty biotech operations, Luu thrives in rapidly changing, highly competitive environments and specializes in business development, corporate restructuring, sales optimization, and process improvement to drive corporate revenue. Schreiner brings more than 25 years of biopharma experience to ImmunityBio. She will be responsible for developing the company’s global payer, reimbursement, and distribution strategies, as well as managing patient access and key accounts. Prior to her role at Stemline Therapeutics, Schreiner held market access roles with Dendreon, Lash Group (AmerisourceBergen), Immunex, and CTI Biopharma. She also led strategic planning and process improvement projects at Deloitte Management Consulting for health plans and physician organizations. Luu joinsImmunityBio effective September 7, 2021, while Schreiner joins the company effective September 13, 2021.